Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doron Markovits

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Israel Medical Association Journal : IMAJ|May 8, 2020
The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-UpYolanda Braun-Moscovici, Yonit Tavor, Doron Markovits, et al.
The Journal of Rheumatology|October 10, 2008
Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosisYolanda Braun-Moscovici, Daniel E Furst, Doron Markovits, et al.
Clinical Rheumatology|April 3, 2007
Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosisAlexandra Balbir-Gurman, Yolanda Braun-Moscovici, Vladimir Livshitz, et al.
Seminars in Arthritis and Rheumatism|August 2, 2011
Pulmonary arteries involvement in Takayasu's arteritis: two cases and literature reviewKohava Toledano, Ludmila Guralnik, Avraham Lorber, et al.
Annals of the Rheumatic Diseases|June 19, 2021
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun, et al.
Clinical and Experimental Rheumatology|September 5, 2022
Switching from intravenous tocilizumab to subcutaneous administration during COVID-19 pandemic: impact on treatment efficacy and patient satisfactionRula Daood, Kochava Toledano, Doron Markovits, et al.
Rheumatology International|December 15, 2012
Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experienceYolanda Braun-Moscovici, Yonatan Butbul-Aviel, Ludmila Guralnik, et al.
The Journal of Rheumatology|March 3, 2006
Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritisYolanda Braun-Moscovici, Doron Markovits, Oren Zinder, et al.
Harefuah|August 9, 2017
[THE INPUT OF MEASURING INFLIXIMAB LEVELS AND LEVELS OF ANTIBODIES TO INFLIXIMAB IN THE MANAGEMENT OF PATIENTS WITH RHEUMATIC DISEASES]Yolanda Braun-Moscovici, Amir Dagan, Kochava Toledano, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 21, 2010
Large leg ulcers due to autoimmune diseasesAlexander P Rozin, Dana Egozi, Yehuda Ramon, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Israel Medical Association Journal : IMAJ|May 8, 2020
The Effects of Adalimumab in Behçet Disease Patients on Clinical Manifestations and on Pro-Inflammatory Cytokines Milieu: Long-Term Follow-UpYolanda Braun-Moscovici, Yonit Tavor, Doron Markovits, et al.
The Journal of Rheumatology|October 10, 2008
Vitamin D, parathyroid hormone, and acroosteolysis in systemic sclerosisYolanda Braun-Moscovici, Daniel E Furst, Doron Markovits, et al.
Clinical Rheumatology|April 3, 2007
Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosisAlexandra Balbir-Gurman, Yolanda Braun-Moscovici, Vladimir Livshitz, et al.
Seminars in Arthritis and Rheumatism|August 2, 2011
Pulmonary arteries involvement in Takayasu's arteritis: two cases and literature reviewKohava Toledano, Ludmila Guralnik, Avraham Lorber, et al.
Annals of the Rheumatic Diseases|June 19, 2021
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun, et al.
Clinical and Experimental Rheumatology|September 5, 2022
Switching from intravenous tocilizumab to subcutaneous administration during COVID-19 pandemic: impact on treatment efficacy and patient satisfactionRula Daood, Kochava Toledano, Doron Markovits, et al.
Rheumatology International|December 15, 2012
Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experienceYolanda Braun-Moscovici, Yonatan Butbul-Aviel, Ludmila Guralnik, et al.
The Journal of Rheumatology|March 3, 2006
Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritisYolanda Braun-Moscovici, Doron Markovits, Oren Zinder, et al.
Harefuah|August 9, 2017
[THE INPUT OF MEASURING INFLIXIMAB LEVELS AND LEVELS OF ANTIBODIES TO INFLIXIMAB IN THE MANAGEMENT OF PATIENTS WITH RHEUMATIC DISEASES]Yolanda Braun-Moscovici, Amir Dagan, Kochava Toledano, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 21, 2010
Large leg ulcers due to autoimmune diseasesAlexander P Rozin, Dana Egozi, Yehuda Ramon, et al.
Pageof 3